Listen to what Dr. Arthur Frankel and Peter MacDonald, SVP of Corporate & Business Development of Stemline Therapeutics, have to say about LLS, the role TAP played in the development of Elzonris and the value TAP created for Stemline beyond the funding amount.
Elzonris® is the first approved therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer.
Beat AML
Coloring Outside the Lines, a new documentary from award-winning independent filmmakers and LLS, follows four cancer patients given months or less to live and chronicles their experience in the Beat AML trial.
Watch: Donna Kelley’s experience with Beat AML
PedAL
Through the Pediatric Acute Leukemia Master Clinical Trial (PedAL), LLS is setting out to fundamentally change how children with pediatric acute leukemia are treated. Hear from PedAL leaders, including Dr. Gwen Nichols, LLS Chief Medical Officer about the impact the trial will have on transforming treatment and care for children with acute leukemias.
